Clinical Trials Logo

Ovarian Neoplasms clinical trials

View clinical trials related to Ovarian Neoplasms.

Filter by:

NCT ID: NCT04999605 Terminated - Ovarian Cancer Clinical Trials

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Start date: June 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.

NCT ID: NCT04907968 Terminated - Clinical trials for Platinum-sensitive Ovarian Cancer (UPGRADE-A)

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

UPGRADE
Start date: June 11, 2021
Phase: Phase 1
Study type: Interventional

Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). The trial consists of dose escalation (DES) and expansion (EXP) portion. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity.

NCT ID: NCT04893551 Terminated - Ovarian Neoplasms Clinical Trials

A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Start date: February 25, 2021
Phase: Phase 1
Study type: Interventional

The primary purpose is to assess the safety and tolerability of tilvestamab following IV administration of multiple doses to participants with HGSOC who have been treated with at least 1 complete course of platinum-based chemotherapy and whose disease has relapsed with platinum resistance ([PRR]-HGSOC) and to determine the plasma pharmacokinetics (PK) exposure by comprehensive profiling (at single dose and steady-state) of multiple ascending doses of tilvestamab.

NCT ID: NCT04891185 Terminated - Ovarian Cancer Clinical Trials

Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

VIPIDO
Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

Visualise peritoneal lesions of epithelial ovarian cancer (EOC) in both primary and interval debulking surgery by using intravascular indocyanine green (ICG) and near-infrared (NIR) light. This Trial wants to investigate whether ICG can increase the visibility of peritoneal lesions and can differentiate between peritoneal implants and fibrosis.

NCT ID: NCT04875806 Terminated - Breast Cancer Clinical Trials

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Start date: June 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

NCT ID: NCT04729608 Terminated - Clinical trials for Platinum-resistant Ovarian Cancer

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

AXLerate-OC
Start date: April 22, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.

NCT ID: NCT04718376 Terminated - Clinical trials for Platinum-resistant Ovarian Cancer

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.

NCT ID: NCT04668521 Terminated - Adnexal Mass Clinical Trials

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

OVA360
Start date: May 4, 2020
Phase:
Study type: Observational

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

NCT ID: NCT04665921 Terminated - Clinical trials for Colorectal Neoplasms

A Study of SGN-STNV in Advanced Solid Tumors

Start date: January 18, 2021
Phase: Phase 1
Study type: Interventional

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

NCT ID: NCT04644315 Terminated - Melanoma Clinical Trials

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

ALpha-T
Start date: May 24, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.